Moonlake Immunotherapeutics (MLTX) — SEC Filings
Moonlake Immunotherapeutics (MLTX) — 32 SEC filings. Latest: 10-Q (May 11, 2026). Includes 12 8-K, 6 10-Q, 4 SC 13G/A.
View Moonlake Immunotherapeutics on SEC EDGAR
Overview
Moonlake Immunotherapeutics (MLTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 144 filed on Apr 1, 2026: On March 31, 2026, BVF Partners L.P./IL, a reporting entity, filed a Form 144 to report the proposed sale of securities related to MoonLake Immunotherapeutics. The filing indicates a planned transaction involving securities of MoonLake Immunotherapeutics, a company in the Pharmaceutical Preparations
Sentiment Summary
Across 32 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 28 neutral. The dominant filing sentiment for Moonlake Immunotherapeutics is neutral.
Filing Type Overview
Moonlake Immunotherapeutics (MLTX) has filed 1 4, 1 144, 6 10-Q, 12 8-K, 2 DEF 14A, 2 10-K, 4 SC 13G/A, 2 SC 13D/A, 1 10-K/A, 1 SC 13G with the SEC between Feb 2024 to May 2026.
Filings by Year
Recent SEC Filings (32)
Risk Profile
Risk Assessment: Of MLTX's 25 recent filings, 2 were flagged as high-risk, 11 as medium-risk, and 12 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$167.303M |
| EPS | -$1.10 |
| Debt-to-Equity | 0.42 |
| Cash Position | $350.736M |
| Operating Margin | N/A |
| Total Assets | $414.335M |
| Total Debt | $73.741M |
Key Executives
- Chief Executive Officer
- Dr. Kristian Reich
- Dr. Oliver Schuh
- Dr. Christian Schetter
- James Kratky
- Dr. Jorge Santos da Sil
- Dr. Jorge Santos DaSilva
- Abigail P. Johnson
Industry Context
MoonLake Immunotherapeutics operates in the highly competitive biotechnology sector, focusing on immunotherapies for inflammatory diseases. The industry is characterized by significant R&D investment, long development cycles, and high regulatory hurdles. Success hinges on the efficacy and safety of novel drug candidates like Sonelokimab, facing competition from established pharmaceutical companies and other emerging biotechs.
Top Tags
pharmaceuticals (5) · biotech (4) · 10-Q (3) · material-agreement (2) · Biotechnology (2) · 8-K (2) · corporate-action (2) · shareholder-vote (2) · acquisition (2) · 10-K (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Commission File Number | 001-39630 | Identifies the company's SEC filing history |
| Film Number | 251455241 | Internal SEC processing number |
| Net Loss | $167.303M | Increased from $74.849M for the nine months ended September 30, 2024 |
| Research and Development Expenses | $146.856M | Increased from $72.412M for the nine months ended September 30, 2024 |
| Cash and Cash Equivalents | $350.736M | Increased from $180.426M at December 31, 2024 |
| Proceeds from Long-Term Debt | $73.022M | New debt incurred during the nine months ended September 30, 2025 |
| Total Liabilities | $123.144M | Increased from $24.542M at December 31, 2024 |
| Total Assets | $414.335M | Decreased from $477.933M at December 31, 2024 |
| Basic and Diluted Net Loss Per Share | $1.10 | For the three months ended September 30, 2025, up from $0.56 in 2024 |
| Revenue | $0 | for the six months ended June 30, 2025, indicating clinical-stage status |
| Period End Date | 2025-06-30 | latest reporting period for the 10-Q |
| SEC File Number | 001-39630 | identifies the company's registration with the SEC |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the financial quarter covered by the report. |
| Filing Date | 2025-05-12 | The date the report was officially submitted to the SEC. |
| Previous Year End Date | 2024-12-31 | Provides a comparison point to the current reporting period. |
Forward-Looking Statements
- {"claim":"MoonLake Immunotherapeutics' stock price may see increased stability or upward pressure due to institutional confidence.","entity":"MoonLake Immunotherapeutics","targetDate":"Next 3-6 months","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Moonlake Immunotherapeutics (MLTX)?
Moonlake Immunotherapeutics has 32 recent SEC filings from Feb 2024 to May 2026, including 12 8-K, 6 10-Q, 4 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MLTX filings?
Across 32 filings, the sentiment breakdown is: 2 bullish, 2 bearish, 28 neutral. The dominant sentiment is neutral.
Where can I find Moonlake Immunotherapeutics SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Moonlake Immunotherapeutics (MLTX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Moonlake Immunotherapeutics?
Key financial highlights from Moonlake Immunotherapeutics's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for MLTX?
The investment thesis for MLTX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Moonlake Immunotherapeutics?
Key executives identified across Moonlake Immunotherapeutics's filings include Chief Executive Officer, Dr. Kristian Reich, Dr. Oliver Schuh, Dr. Christian Schetter, James Kratky and 3 others.
What are the main risk factors for Moonlake Immunotherapeutics stock?
Of MLTX's 25 assessed filings, 2 were flagged high-risk, 11 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Moonlake Immunotherapeutics?
Recent forward-looking statements from Moonlake Immunotherapeutics include guidance on {"claim":"MoonLake Immunotherapeutics' stock price may see increased stability or upward pressure due to institutional c.